NEEVO DHA Rx
Generic Name and Formulations:
L-methylfolate (as Metafolin) 1.13mg, thiamine 1.4mg, riboflavin 1.4mg, niacinamide 18mg, pyridoxine 25mg, Vit. B12 1mg, Vit.C 85mg, Vit.D3 5mcg, Vit.E 15 IU, calcium (as carbonate) 110mg, iron (ferrous fumarate) 27mg, iodide (as potassium iodide) 220mcg, magnesium (as oxide) 60mg, selenium 60mcg, docosahexaenoic acid (DHA, vegetarian source [algal oil]) 581.92mg; caps; contains soy, gelatin, sorbitol, glycerin.
Alfasigma USA, Inc.
Indications for NEEVO DHA:
Nutritional supplement during pregnancy, prenatal, and postnatal periods in women with dietary needs for the biologically active form of folate, who are at risk for hyperhomocysteinemia, impaired folic acid absorption, and/or impaired folic acid metabolism due to 677C>T mutations in the MTHFR gene.
1 cap daily.
Wilson's disease. Hemochromatosis. Treatment of pernicious or other megaloblastic anemias.
Folic acid may mask pernicious anemia. DHA: bleeding diatheses.
May antagonize levodopa, phenytoin. DHA: avoid anticoagulants.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies